Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Life Technologies Acquires Compendia Bioscience

Published: Tuesday, October 09, 2012
Last Updated: Tuesday, October 09, 2012
Bookmark and Share
Bioinformatics expertise will enable deeper engagement with established customer base of leading pharmaceutical companies.

Life Technologies has announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and proteome analysis.

Compendia's existing business, which will continue under the leadership of its current management team, adds an established base of pharmaceutical industry customers for Life Technologies' platforms. Compendia's oncology data is widely utilized by leading pharmaceutical companies in their drug development work and will extend Life's abilities to both develop its own tests and to partner with pharmaceutical companies in companion diagnostic development.

"We have created the optimal foundation to drive progress in personalized medicine," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "By combining the acquisitions of Pinpoint Genomics, Navigenics and Compendia, we now possess the full spectrum capability to develop and commercialize high-value cancer diagnostics where there is currently great unmet need."

The recent launch of Pervenio™ Lung RS, a first-of-its-kind prognostic test, underscores Life Technologies' strategy to focus initially on lung cancer, a highly underserved disease. The company plans to utilize the extensive content in Compendia to springboard to other areas of oncology.

Preeminent Assets Widely Used by Leading Pharmaceutical Companies

Compendia holds one of the world's largest and most comprehensive sets of mutation profiles, gene expression data and cellular biomarkers that have been gathered from more than 62,000 cancer patients. Oncomine™, the company's cloud-based analytics tool, integrates high-throughput cancer profiling data across a large volume of cancer types to allow users to mine it for correlations among genetic signatures, clinical status, and drug response markers.

The proprietary technology is especially useful to Compendia's well-established pharmaceutical customer base. They use it to ascertain the genes most frequently mutated across thousands of samples of a given cancer type, as well as the biomarkers associated with biological responses to specific classes of compounds. Equally valuable is Compendia's OncoScore™ product, a tool that helps optimize the clinical trials process by stratifying patients based on genetic signatures so that individuals most likely to respond to specific drugs are included.

"Compendia has become an integral part of the pharmaceutical industry's cancer drug discovery programs, and in joining Life Technologies, we'll gain the opportunity to expand the utility of Compendia even further," said Daniel R. Rhodes, Compendia's Chief Executive Officer and co-founder, who will join Life Technologies following the acquisition.

Compendia co-founder Arul Chinnaiyan, M.D., Ph.D., a pioneer in the field of cancer research, will serve as strategic advisor to Life Technologies, helping to shape the company's further steps into personalized medicine.

Cancer Biology Expertise Enhances Life's Diagnostics Development Capability

"Compendia is highly regarded by its customers as a preeminent source of cancer biology expertise," said Ronnie Andrews, President of Medical Sciences at Life Technologies. "That expertise will serve as a content engine to drive development of diagnostic content across the breadth of Life platforms.

"Initially, tests like Pervenio™ Lung RS, will be offered as a service through our CLIA laboratory, but our longer-term goal is to commercialize diagnostic products on Life platforms for use in hospitals labs, where the majority of patients are treated," Andrews said. "All patients should have access to an opportunity to benefit from the extensive knowledge base that has been gained through decades of research."

In addition to enabling Life Technologies' ability to develop its own lab-developed and commercial tests, the Compendia acquisition will enhance Life's companion diagnostics effort and positions the company as a partner of choice for pharma. Life can now offer best-in-class products and services for target discovery and validation, biomarker analysis, clinical sample testing, companion diagnostics development and clinical implementation.

Life Technologies plans to develop a clinical version of Oncomine™, which will allow physicians to compare their patients' genetic signatures against large data sets to determine the most effective drug protocols. A seamless transfer of the bioinformatics data into easy-to-use, actionable information will be possible with the treating physician portal repurposed from the Navigenics acquisition.

Life Technologies will also incorporate the Compendia oncology workflow within its Ion Reporter™ software to accelerate its lead in building the most robust bioinformatics offering in the industry. Researchers sequencing tumor samples on the Ion Personal Genome Machine (PGM™), for example, will be able to leverage the insight gained from the thousands of samples already in Compendia's database in an effort to identify targetable mutations.

The acquisition represents another significant step in Life Technologies' strategy to develop its medical sciences business through internal development, partnerships and select acquisitions. The financial terms of the deal are not being disclosed. The acquisition of Compendia Bioscience is expected to be neutral to 2012 earnings and accretive to the company's overall ROIC by 2015.

Ion Reporter™ and Ion Personal Genome Machine™ are Research Use Only and not intended for use in diagnostic procedures.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KACST Partners with Life Tech in The Saudi Human Genome Program
Program aims to analyze 100,000 human genomes to identify the causes of disease in the population of the Kingdom of Saudi Arabia and the Arab world.
Monday, December 09, 2013
Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
The five Innovation Grant recipients in the Digital PCR Applications Grant Program was announced during the ASHG conference in Boston.
Thursday, October 24, 2013
Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Announces Second Quarter 2013 Results
Revenue increased 1% excluding impact of currency.
Thursday, August 01, 2013
Life Technologies Signs Five-Year Agreement with the FDA
The agreement aims to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Tuesday, July 30, 2013
Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
Life Technologies Corporation announced that the new Center for Personalized Medicine at Roswell Park Cancer Institute has purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ sequencers.
Thursday, February 21, 2013
Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a Clinical Genomics Company
Spinoff venture will develop genomic sequencing solutions utilizing Ion Torrent technology for clinical applications.
Thursday, January 10, 2013
Life Technologies introduces Ion AmpliSeq™ Community Panels
Ion AmpliSeq™ Community Panels leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.
Wednesday, November 07, 2012
Life Technologies Acquires Compendia Bioscience
Acquisition expands Life Technologies' ability to drive progress in personalized medicine
Sunday, October 14, 2012
Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium
Pioneering joint venture releases 58 of 200 planned, highly-specific recombinant antibodies for epigenetic studies.
Thursday, July 19, 2012
Life Technologies Collaborate with University of North Texas Health Science Center
University of North Texas Health Science Center advances forensic research by investing in semiconductor DNA sequencing technology.
Thursday, June 21, 2012
SickKids Adopts Life Technologies' Ion Proton™ Sequencer to Launch New Centre for Genetic Medicine
Long-term partnership will focus on sequencing 10,000 genomes per year to revolutionize pediatric disease research in Canada.
Thursday, June 21, 2012
Life Technologies Teams with Universitry of North Texas
University Advances Forensic Research by Investing in Semiconductor DNA Sequencing Technology.
Thursday, June 21, 2012
Celebrating the 10th Anniversary of the Human Genome Project's Completion
Life Technologies Foundation announces lead sponsorship of Smithsonian exhibit.
Tuesday, May 22, 2012
Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos